<DOC>
	<DOCNO>NCT02310243</DOCNO>
	<brief_summary>Diagnosis : Acute myeloid leukemia ; Acute lymphoblastic leukemia Age ≥ 18 year , upper age limit Study drug : Palbociclib Phase Ib/IIa , open-label - Phase Ib : Based previous experience 125 mg palbociclib daily 21 day follow 7 day rest patient breast cancer , liposarcoma , non-small cell lung cancer , hepatocellular carcinoma , ovarian cancer , mantle-cell lymphoma , glioblastoma , regimen choose first dose evaluated phase Ib . Based 3 + 3 modified Fibonacci design , tolerable dose palbociclib phase IIa define . - Phase IIa : single-agent palbociclib use tolerable dose define phase Ib part study administer daily 21 day follow 7 day rest . Based optimal two-stage design Simon , 21 patient treat first stage . If result positive , 29 additional patient recruit second stage study . An efficacy investigational therapy reject first stage 21 treated patient two less patient achieve complete remission ( CR ) , CR incomplete blood count recovery ( CRi ) , partial remission ( PR ) , anti-leukemic effect ( ALE ) . If three patient achieve CR , CRi , PR , ALE first stage , trial intend continued second stage total sample size 50 patient . Start recruitment : July 2015 End recruitment : July 2017 End study ( last patient ) : July 2018 The treatment duration individual patient estimate 2-6 month , may unlimited patient sustain response ( `` case-by-case decision '' ) . Observation time per patient entry study ( incl . treatment ) least 12 month .</brief_summary>
	<brief_title>Study Palbociclib MLL-rearranged Acute Leukemias</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<criteria>Patients confirm diagnosis acute leukemia MLL rearrangement accord 2008 WHO Classification Patients MLLrearranged leukemia refractory standard induction therapy immediate candidate allogeneic HSCT ( bridge transplant allow ) Patients MLLrearranged leukemia relapse standard firstline treatment immediate candidate allogeneic HSCT ( bridge transplant allow ) Patients newly diagnose MLLrearranged leukemia eligible intensive firstline therapy Genetic/histologic/immunohistologic assessment one central laboratory Age ≥ 18 year , upper age limit WHO performance status ≤ 2 No prior chemotherapy two week study entry except hydroxyurea control hyperleukocytosis Nonpregnant nonnursing . Women childbearing potential must negative serum urine pregnancy test sensitivity least 25 mIU/mL within 72 hour prior registration ( WOCBP define sexually active mature woman undergone hysterectomy menses time precede 24 month ) . Female patient reproductive age male patient must agree avoid get pregnant father child therapy three month last dose therapy . Women childbearing potential must either commit continued abstinence heterosexual intercourse begin one acceptable method birth control ( IUD , tubal ligation , partner 's vasectomy ) . Hormonal contraception inadequate method birth control . Men must agree father child must use latex condom sexual contact WOCBP receive therapy three month therapy stop , even undergone successful vasectomy . Signed write informed consent Prior treatment palbociclib Performance status &gt; 2 accord WHO criteria Organ insufficiency : creatinine &gt; 1.5 x upper normal serum level ; bilirubin , AST , AP &gt; 2.5 x upper normal serum level ; heart failure NYHA III/IV ; uncontrolled hypertension ; unstable angina ; serious cardiac arrhythmia ; severe obstructive restrictive ventilation disorder Uncontrolled infection Patients `` currently active '' second malignancy nonmelanoma skin cancer . Patients consider `` currently active '' malignancy complete therapy consider physician less 30 % risk relapse within one year . Severe neurologic psychiatric disorder interfere ability give informed consent Known suspect active alcohol drug abuse Known positivity HIV , active HAV , HBV , HCV infection Bleeding disorder unrelated leukemia Uncontrolled CNS involvement ( treatment CNSinvolvement prior inclusion allow ) QTc &gt; 470 msec ( base mean value triplicate ECGs ) , family personal history long short QT syndrome , Brugada syndrome , know history QTc prolongation Torsade de Pointes Uncontrolled electrolyte disorder aggravate effect QTcprolonging drug ( e.g. , hypocalcemia , hypokalemia , hypomagnesemia ) No consent registration , storage , process individual disease characteristic , information course disease , information obtain family physician and/or physician involve treatment patient study participation No consent biobanking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>MLL-rearranged leukemia</keyword>
	<keyword>Palbociclib ( PD-0332991-00 )</keyword>
</DOC>